Market Place
Sourcing Support
Provectus BioPharma Launches VisiRose for Ophthalmology Treatments
11 Dec 2024 //
GLOBENEWSWIRE
VisiRose Introduces Revolutionary Therapy for Eye Infections
10 Dec 2024 //
ACCESSWIRE
Provectus Announces Q4 2024 Investor Webinar
24 Oct 2024 //
GLOBENEWSWIRE
Provectus Biopharma Announces Q4 2024 Conference Call
10 Oct 2024 //
GLOBENEWSWIRE
Provectus Announces Investor Webinar for 2024 Annual Meeting of Stockholders
13 Jun 2024 //
GLOBENEWSWIRE
Provectus Presents Rose Bengal Wound Treatment Poster At SID
21 May 2024 //
GLOBENEWSWIRE
Provectus Presents Rose Bengal Antimicrobial Data At ARVO 2024
14 May 2024 //
GLOBENEWSWIRE
Provectus: Patent For Oral Rose Bengal In Leukemia
02 May 2024 //
GLOBENEWSWIRE
Provectus: Preclinical Data On Oral Rose Bengal For Cancer
18 Apr 2024 //
GLOBENEWSWIRE
Provectus Adds Management, Reiterates Commitment to Shareholder Value Creation
16 Apr 2024 //
GLOBENEWSWIRE
Provectus: PV-10 HNSCC Cancer Immunotherapy Poster At AACR 2024
11 Apr 2024 //
GLOBENEWSWIRE
Provectus License Agreement for Photodynamic Antimicrobial Treatment
27 Mar 2024 //
GLOBENEWSWIRE
Provectus Announces Award for U.S. Patents of Rose Bengal Sodium
12 Mar 2024 //
GLOBENEWSWIRE
Provectus Announces Acceptance of Cancer Immunotherapy PV-10 Abstract
07 Mar 2024 //
GLOBENEWSWIRE
Provectus Announces Acceptance of Grade Rose Bengal Sodium Abstract
29 Feb 2024 //
GLOBENEWSWIRE
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
15 Feb 2024 //
GLOBENEWSWIRE
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
14 Feb 2024 //
GLOBENEWSWIRE
Provectus Announces Notice of Allowance of First Patent of Rose Bengal Sodium
18 Dec 2023 //
GLOBENEWSWIRE
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10
15 Nov 2023 //
GLOBENEWSWIRE
Provectus Provides Updated Data on Cancer Immunotherapy PV-10
13 Nov 2023 //
GLOBENEWSWIRE
Provectus Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data
06 Nov 2023 //
GLOBENEWSWIRE
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation
07 Aug 2023 //
GLOBENEWSWIRE
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations
01 Aug 2023 //
GLOBENEWSWIRE
Provectus Announces Acceptance of PV-10® Immunotherapy Abstracts
28 Apr 2021 //
GLOBENEWSWIRE
Provectus Announces Publication of Australian Compassionate Use Patients
31 Mar 2021 //
GLOBENEWSWIRE
Provectus Biopharmaceuticals Announces Publication of Australian Compassionate
31 Mar 2021 //
GLOBENEWSWIRE
Provectus Receives Notice of Allowance for Adult Solid Tumor Cancer PV-10®
30 Mar 2021 //
BLOOMBERG
Provectus Highlights Outcome from Combination Trial of PV-10® and KEYTRUDA®
21 Sep 2020 //
GLOBENEWSWIRE
Provectus shows Data from Combination Therapy Trial of PV-10 and KEYTRUDA
17 Sep 2020 //
GLOBENEWSWIRE
